Logo image of BU.CA

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

TSX:BU - Toronto Stock Exchange - CA1208311029 - Common Stock - Currency: CAD

0.1  0 (-4.76%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BU. BU was compared to 32 industry peers in the Chemicals industry. Both the profitability and financial health of BU have multiple concerns. BU has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year BU has reported negative net income.
BU had a negative operating cash flow in the past year.
BU had negative earnings in each of the past 5 years.
BU had a negative operating cash flow in each of the past 5 years.
BU.CA Yearly Net Income VS EBIT VS OCF VS FCFBU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of BU (-87.03%) is worse than 82.76% of its industry peers.
Looking at the Return On Equity, with a value of -502.81%, BU is doing worse than 86.21% of the companies in the same industry.
Industry RankSector Rank
ROA -87.03%
ROE -502.81%
ROIC N/A
ROA(3y)-116.26%
ROA(5y)-73.05%
ROE(3y)-264.46%
ROE(5y)-163.05%
ROIC(3y)N/A
ROIC(5y)N/A
BU.CA Yearly ROA, ROE, ROICBU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

1.3 Margins

BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BU.CA Yearly Profit, Operating, Gross MarginsBU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

1

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
BU has more shares outstanding than it did 1 year ago.
BU has more shares outstanding than it did 5 years ago.
BU has a better debt/assets ratio than last year.
BU.CA Yearly Shares OutstandingBU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BU.CA Yearly Total Debt VS Total AssetsBU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

BU has an Altman-Z score of -22.31. This is a bad value and indicates that BU is not financially healthy and even has some risk of bankruptcy.
BU's Altman-Z score of -22.31 is on the low side compared to the rest of the industry. BU is outperformed by 82.76% of its industry peers.
A Debt/Equity ratio of 0.66 indicates that BU is somewhat dependend on debt financing.
BU has a Debt to Equity ratio of 0.66. This is in the lower half of the industry: BU underperforms 72.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF N/A
Altman-Z -22.31
ROIC/WACCN/A
WACC6.8%
BU.CA Yearly LT Debt VS Equity VS FCFBU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.30 indicates that BU may have some problems paying its short term obligations.
BU's Current ratio of 0.30 is on the low side compared to the rest of the industry. BU is outperformed by 75.86% of its industry peers.
A Quick Ratio of 0.27 indicates that BU may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.27, BU is doing worse than 62.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.27
BU.CA Yearly Current Assets VS Current LiabilitesBU.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

6

3. Growth

3.1 Past

BU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.59%, which is quite impressive.
The Revenue for BU has decreased by -18.51% in the past year. This is quite bad
The Revenue has been growing by 35.74% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)72.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.73%
Revenue 1Y (TTM)-18.51%
Revenue growth 3Y-10.83%
Revenue growth 5Y35.74%
Sales Q2Q%-79.14%

3.2 Future

The Earnings Per Share is expected to grow by 52.09% on average over the next years. This is a very strong growth
BU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 128.44% yearly.
EPS Next Y37.38%
EPS Next 2Y52.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-17.09%
Revenue Next 2Y128.44%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BU.CA Yearly Revenue VS EstimatesBU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
BU.CA Yearly EPS VS EstimatesBU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

4

4. Valuation

4.1 Price/Earnings Ratio

BU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 5.87, the valuation of BU can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BU indicates a rather cheap valuation: BU is cheaper than 96.55% of the companies listed in the same industry.
BU is valuated cheaply when we compare the Price/Forward Earnings ratio to 94.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.87
BU.CA Price Earnings VS Forward Price EarningsBU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BU.CA Per share dataBU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BU's earnings are expected to grow with 52.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.09%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for BU!.
Industry RankSector Rank
Dividend Yield N/A

BURCON NUTRASCIENCE CORP

TSX:BU (2/7/2025, 7:00:00 PM)

0.1

0 (-4.76%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)02-18 2025-02-18
Inst Owners0.21%
Inst Owner ChangeN/A
Ins Owners27.74%
Ins Owner ChangeN/A
Market Cap14.26M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)17.3%
EPS NY rev (3m)-10.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-46.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.87
P/S 51.48
P/FCF N/A
P/OCF N/A
P/B 8.61
P/tB 35.59
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)0.02
Fwd EY17.04%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0.01
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.03%
ROE -502.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.26%
ROA(5y)-73.05%
ROE(3y)-264.46%
ROE(5y)-163.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.23%
Cap/Sales 100.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.27
Altman-Z -22.31
F-Score4
WACC6.8%
ROIC/WACCN/A
Cap/Depr(3y)75.59%
Cap/Depr(5y)243.69%
Cap/Sales(3y)66.12%
Cap/Sales(5y)174.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.73%
EPS Next Y37.38%
EPS Next 2Y52.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.51%
Revenue growth 3Y-10.83%
Revenue growth 5Y35.74%
Sales Q2Q%-79.14%
Revenue Next Year-17.09%
Revenue Next 2Y128.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.17%
OCF growth 3YN/A
OCF growth 5YN/A